Multi-Center Phase Ib Study of Intermittent Dosing of the MEK Inhibitor, Selumetinib, in Patients With Advanced Uveal Melanoma Not Previously Treated With a MEK Inhibitor

Trial Profile

Multi-Center Phase Ib Study of Intermittent Dosing of the MEK Inhibitor, Selumetinib, in Patients With Advanced Uveal Melanoma Not Previously Treated With a MEK Inhibitor

Recruiting
Phase of Trial: Phase I

Latest Information Update: 29 Dec 2017

At a glance

  • Drugs Selumetinib (Primary)
  • Indications Uveal melanoma
  • Focus Adverse reactions
  • Most Recent Events

    • 21 Dec 2017 Planned End Date changed from 1 Jan 2018 to 1 Jan 2019.
    • 21 Dec 2017 Planned primary completion date changed from 1 Sep 2017 to 1 Sep 2018.
    • 06 Jun 2017 Trial design presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top